High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers

about

High-dose therapy with peripheral blood stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive metastatic breast cancers

Item

http://www.wikidata.org/entity/Q58215312

description

im Juni 1998 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 June 1998

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в червні 1998

@uk

name

High-dose therapy with periphe ...... sive metastatic breast cancers

@en

High-dose therapy with peripheral blood stem cell

@nl

type

Item

label

High-dose therapy with periphe ...... sive metastatic breast cancers

@en

High-dose therapy with peripheral blood stem cell

@nl

prefLabel

High-dose therapy with periphe ...... sive metastatic breast cancers

@en

High-dose therapy with peripheral blood stem cell

@nl

P1476

High-dose therapy with periphe ...... sive metastatic breast cancers

@en

P2093

D T Lin

http://www.w3.org/2001/XMLSchema#string

J F Lin

http://www.w3.org/2001/XMLSchema#string

K J Chang

http://www.w3.org/2001/XMLSchema#string

L T Lui

http://www.w3.org/2001/XMLSchema#string

M T Lin

http://www.w3.org/2001/XMLSchema#string

S C Yu

http://www.w3.org/2001/XMLSchema#string

Y C Chen

http://www.w3.org/2001/XMLSchema#string

Y S Chang

http://www.w3.org/2001/XMLSchema#string

P2860

A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group

Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.

High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.

Dose-response in the treatment of breast cancer: a critical review.

Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer.

A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.

Multiparametric prognostic evaluation of biological factors in primary breast cancer.

P2888

a:1006023731381

P304

237-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1023/A:1006023731381

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ann-Lii Cheng

Jih-Luh Tang

Kun-Huei Yeh

P577

1998-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1029026284

http://www.w3.org/2001/XMLSchema#string

P698

9776507

http://www.w3.org/2001/XMLSchema#string